Commercial-scale manufacture of lentivirus for <i>ex vivo</i> and <i>in vivo</i> therapies

As the field of lentivirus (LV) progresses toward large-scale manufacturing to generate sufficient functional LVs for treating patients, scalability and consistency are important aspects to consider. This poster presents case study data to show how TFDF enables a scalable perfusion process that can provide sufficient LV doses for large patient populations.